Search Results

Featured Stories

Toggle

Showing 10 of 122 results

Teva Reports First Quarter 2021 Financial Results

Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full year 2021 business outlook...

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

  TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020. This press release...

Teva Reports Third Quarter 2020 Financial Results

Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net revenues of $16.5-16.8 billio...

Teva Reports Second Quarter 2020 Financial Results

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2020.

Teva Reports First Quarter 2020 Financial Results

Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITD...

Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, 2020

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter financial results on Thursday, May 7, 2020 at 7:00 a.m. ET. Followi...

Teva Reports Fourth Quarter and Full Year 2019 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2019. Full-Year 2019 and Q4 2019 Highlights :       FY 2019   Q4 201...

Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2019 financial results, as well as on its financial...

Teva Reports Third Quarter 2019 Financial Results

Revenues of $4.3 billion GAAP diluted loss per share of $0.29 Non-GAAP diluted EPS of $0.58 Free cash flow of $551 million Spend base reduction of $2.9 billion since initiation of the restructuring...

Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7,

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. E...